2365193-22-0
Chemical Structure
Zelasudil
Synonym(s): RXC007
- CAS. Nr.: 2365193-22-0
- Formula:C22H21F2N7O
- Molecular Weight:437.45
IUPAC Name: 4-(5-((4-cyclopropyl-1H-indazol-5-yl)amino)-1-methyl-1H-1,2,4-triazol-3-yl)-N-(2,2-difluoroethyl)benzamide
InChIKey: HSZPZEGJQCFGDE-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(C2=NN(C)C(NC3=CC=C4NN=CC4=C3C5CC5)=N2)C=C1)NCC(F)F
Biological Activity: Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zelasudil | 99.48% | Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee E, et al. Selective ROCK2 inhibition for treatment of edema and associated conditions: World Intellectual Property Organization, WO2022169946. 2022-08-11.
- [2]. WHO Drug Information-World Health Organization (WHO).
- [3]. Pajic M, et al. Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer[J]. Cancer Research, 2024, 84(6_Supplement): 720-720.
- [4]. Gambardella A, et al. Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in ex-vivo and in vivo models of pulmonary fibrosis[C]//European Respiratory Journal. 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND: EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2022, 60.
